About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« . . .And That Settles It | Main | Arcadia's Furnishings »

November 11, 2005

Gene to Drug: You Bet

Email This Entry

Posted by Derek

I mentioned that the Wall Street Journal is running a free-access week. That'll give you a chance to check out the Nov. 11th column by their science columnist, Sharon Begley, who sounds an appropriate note of caution about genomic-based drug discovery. (And I'm not saying that just because she quotes me). It'll be good to get these concepts out to a wider audience.

Comments (8) + TrackBacks (0) | Category: Press Coverage


1. SteveSC on November 11, 2005 3:56 PM writes...

Quoted 4 times no less! And 3 are full paragraphs. Your blog is mentioned twice too. Must have made a very good impression. When will we hear you on Science Friday? ;-)

Permalink to Comment

2. Medchem on November 11, 2005 5:21 PM writes...

Derek, can you give a link to your original block that was quoted?

Permalink to Comment

3. Medchem on November 11, 2005 5:21 PM writes...

Sorry meant to say "blog".

Permalink to Comment

4. JK on November 11, 2005 5:34 PM writes...

Which is not to say that it won't pay off in the end. Think about the distance between William Harvey and the first heart transplant.

Permalink to Comment

5. Mercer Chow on November 14, 2005 7:45 AM writes...

A bit disappointed to see your good name adding credibility to Sharon Begley, who is IMHO the worst (i.e., most credulous) science columnist/reporter in the MSM. Which isn't to say she's always wrong, just that any lay person who read nothing but her would come away with a distorted view of the scientific landscape.

Permalink to Comment

6. Derek Lowe on November 14, 2005 9:42 AM writes...

Well, Mercer, you can at least say that she hasn't fallen for the latest round of genomics hype. . .

Permalink to Comment

7. Rev. Howard Furst on November 14, 2005 4:20 PM writes...

The free access to the WSJ article via the provided link has expired, but it is also posted here:

Permalink to Comment

8. daen on November 16, 2005 11:01 AM writes...

Hákan Hákanarson, VP of Clinical Sciences at deCODE, was here in Copenhagen yesterday to give a presentation on pharmacogenomics in which he talked at length, among other things, about their LTA4 hydrolase inhibitor work. Seems interesting, but let's see how it pans out. For example, I notice there are some doubts being raised about Herceptin's efficacy in the Lancet recently ( - free reg required).

Permalink to Comment


Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry